A detailed history of Grove Bank & Trust transactions in Genmab A/S stock. As of the latest transaction made, Grove Bank & Trust holds 42 shares of GMAB stock, worth $859. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42
Holding current value
$859
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$23.84 - $28.48 $1,001 - $1,196
42 New
42 $1,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Grove Bank & Trust Portfolio

Follow Grove Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grove Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Grove Bank & Trust with notifications on news.